Preferences and Feasibility of Long‐Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low‐ and Middle‐Income Countries
Journal of Viral Hepatitis · 2025
DOI: 10.1111/jvh.14031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Renae Furl und 17 weiteren Autor:innen. Beteiligte Einrichtung: Section of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Patient Acceptance of Health Care, Hepatitis C, Patient Preference. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: unitaid.
Abstract (Originalsprache)
Despite available curative treatments, global rates of hepatitis C virus (HCV) infection persist with significant burden in low‐ and middle‐income countries (LMICs). Long‐acting (LA) antiviral products are in development. This study explored the challenges and opportunities in LA‐HCV treatment across three LMICs: Egypt, Ethiopia and India. The survey focused on understanding barriers and facilitators to treatment, with emphasis on LA treatment preferences. Four‐hundred respondents completed a survey including demographics, HCV treatment history and preferences for injections, implants and microarray patches (MAPs) compared to pills. Overall, 78% of respondents were willing to receive injections, 43% were willing to receive implants and 55% were willing to receive MAPs. Marked heterogeneity in acceptability of non‐oral treatments was observed. Among respondents who had not previously received HCV treatment, 94%, 43%, and 75% were willing to receive injections, implants, or MAPs, respectively. In contrast, among those already cured by oral HCV treatment, 61%, 40% and 43% were willing to receive injections, implants or MAPs. Other characteristics associated with willingness to receive an injection included urban residence, younger age, male sex, higher education level and taking pills for any reason (all results p < 0.001). The most common concern for all LA modalities was lack of effectiveness. Prior experience with injection or implant increased willingness to receive any LA modality ( p < 0.001). Coupled with a point‐of‐care HCV diagnostic test, availability of and willingness to receive HCV treatment delivered by a LA formulation could simplify and expand treatment access in LMICs and contribute towards global HCV elimination goals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Treatment Action Group, New York, USA.
- Division of Infectious Diseases, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Hepatology Department, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt.
ORCID-Profile: Asmaa Gomaa, Sunil Solomon, Susan Swindells
Förderung
- unitaid
Zitieren
APA
Furl, R., Scarsi, K. K., Sayles, H., Anderson, M., Ofimboudem, J. D., Weld, E. D., Waked, I., Gomaa, A., Al-Khatib, A., Elshobary, F. M., Desalegn, H., Fisseha, H., Solomon, S., Mehta, S., Owen, A., Rannard, S., Thomas, D. L., & Swindells, S. (2025). Preferences and Feasibility of Long‐Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low‐ and Middle‐Income Countries. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.14031
Vancouver
Furl R, Scarsi KK, Sayles H, Anderson M, Ofimboudem JD, Weld ED, et al. Preferences and Feasibility of Long‐Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low‐ and Middle‐Income Countries. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.14031
BibTeX
@article{Furl2025,
author = {Furl, Renae and Scarsi, Kimberly K and Sayles, Harlan and Anderson, Matt and Ofimboudem, Joelle Dountio and Weld, Ethel D and Waked, Imam and Gomaa, Asmaa and Al-Khatib, Alzhraa and Elshobary, Fatma Mohammed and Desalegn, Hailemichael and Fisseha, Henok and Solomon, Sunil and Mehta, Shruti and Owen, Andrew and Rannard, Steve and Thomas, David L and Swindells, Susan},
title = {Preferences and Feasibility of Long‐Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low‐ and Middle‐Income Countries},
journal = {Journal of Viral Hepatitis},
year = {2025},
doi = {10.1111/jvh.14031}
}
EUVIMED